# OnCo record donafenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/donafenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "donafenib" ;
  schema:name "Donafenib"@en ;
  schema:description "Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option."@en ;
  schema:url <https://onco.cc/drugs/donafenib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Donafenib> ;
  schema:citation <https://www.zelgen.com/en/>, <https://doi.org/10.1200/JCO.20.02672>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule multi-kinase inhibitor (deuterated sorafenib)" ;
  schema:alternateName "Zepsun" ;
  onco:approval "China 2021: First-line unresectable hepatocellular carcinoma (ZGDH3)", "China 2022: Radioiodine-refractory differentiated thyroid cancer" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/thyroid/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/braf/> ;
  onco:companies <https://onco.cc/companies/zelgen/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/zgdh3/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gordan-j-clin-oncol/> .